Ticagrelor
- Generic Name
- Ticagrelor
- Brand Names
- Brilinta, Brilique
- Drug Type
- Small Molecule
- Chemical Formula
- C23H28F2N6O4S
- CAS Number
- 274693-27-5
- Unique Ingredient Identifier
- GLH0314RVC
- Background
Ticagrelor, or AZD6140, was first described in the literature in 2003. Ticagrelor is an ADP derivative developed for its P2Y receptor antagonism. Unlike clopidogrel, ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,.
Ticagrelor was granted EMA approval on 3 December 2010.
Ticagrelor was granted FDA approval on 20 July 2011.
- Indication
Ticagrelor is indicated to reduce the risk of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome or a history of myocardial infarction. Ticagrelor is also indicated to reduce the risk of a first myocardial infarction or stroke in high risk patients with coronary artery disease.
- Associated Conditions
- Cardiovascular Mortality, Myocardial Infarction, Stroke, Thrombosis (Stent Thrombosis)
- Associated Therapies
- -
Ticagrelor and Anti-inflammatory Effects
- First Posted Date
- 2015-04-02
- Last Posted Date
- 2015-04-02
- Lead Sponsor
- Kyunghee University Medical Center
- Target Recruit Count
- 25
- Registration Number
- NCT02406911
- Locations
- 🇰🇷
Kyung Hee University Hospital, Seoul, Korea, Republic of
Effect of Methylnaltrexone on the PK/PD Profiles of Ticagrelor in Patients Treated With Morphine
- Conditions
- Interventions
- First Posted Date
- 2015-03-31
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- University of Florida
- Target Recruit Count
- 30
- Registration Number
- NCT02403830
- Locations
- 🇺🇸
University of Florida, Jacksonville, Florida, United States
Genotype and Platelet Reactivity in Patients on Hemodialysis
- First Posted Date
- 2015-03-20
- Last Posted Date
- 2015-03-20
- Lead Sponsor
- Kyunghee University Medical Center
- Target Recruit Count
- 20
- Registration Number
- NCT02394145
- Locations
- 🇰🇷
Kyung Hee University Hospital, Seoul, Korea, Republic of
Reversal of the Anti-platelet Effects of Ticagrelor
- Conditions
- Interventions
- First Posted Date
- 2015-03-09
- Last Posted Date
- 2017-08-16
- Target Recruit Count
- 64
- Registration Number
- NCT02383771
- Locations
- 🇨🇳
First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
Effect of Ticagrelor Versus Clopidogrel on Endothelial Dysfunction and Vascular Inflammation
- Conditions
- Interventions
- First Posted Date
- 2015-03-05
- Last Posted Date
- 2016-07-06
- Lead Sponsor
- Kiyuk Chang
- Target Recruit Count
- 38
- Registration Number
- NCT02379676
- Locations
- 🇰🇷
Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea, Republic of
P3AMI Antiplatelet Trial
- First Posted Date
- 2015-03-03
- Last Posted Date
- 2020-02-10
- Lead Sponsor
- The Royal Wolverhampton Hospitals NHS Trust
- Target Recruit Count
- 87
- Registration Number
- NCT02376283
- Locations
- 🇬🇧
The Royal Wolverhampton NHS Trust, Wolverhampton, West Midlands, United Kingdom
The Effect Of Ticagrelor On Saphenous Vein Graft Patency In Patients Undergoing Coronary Artery Bypass Grafting Surgery
- Conditions
- Interventions
- First Posted Date
- 2015-02-02
- Last Posted Date
- 2020-04-27
- Lead Sponsor
- J.M. ten Berg
- Target Recruit Count
- 487
- Registration Number
- NCT02352402
- Locations
- 🇳🇱
Medisch Spectrum Twente, Enschede, Netherlands
🇳🇱Universitair Medisch Centrum Groningen, Groningen, Netherlands
🇳🇱Catharina Ziekenhuis, Eindhoven, Netherlands
Effects and Plasma Concentration of Ticagrelor, After Crushed and Non-crushed Intake, After Acute Coronary Syndrome
- First Posted Date
- 2015-01-19
- Last Posted Date
- 2021-05-10
- Lead Sponsor
- University Hospital, Ghent
- Target Recruit Count
- 40
- Registration Number
- NCT02341729
- Locations
- 🇧🇪
Intensive Care Unit, Ghent University Hospital, Ghent, Belgium
Determine the Safety/Efficacy of Ticagrelor for Maintaining Patency of Arterio-Venous Fistulae Created for Hemodialysis
- Conditions
- Interventions
- First Posted Date
- 2015-01-09
- Last Posted Date
- 2022-06-08
- Lead Sponsor
- University of Virginia
- Target Recruit Count
- 54
- Registration Number
- NCT02335099
- Locations
- 🇺🇸
University of Virginia - Hospital West Kidney Center Dialysis, Charlottesville, Virginia, United States
A Single-center, Prospective,Randomized Study of Antiplatelet Effects of Ticagrelor Versus Clopidogrel in Patients With Dual Anti-platelet Therapy After Coronary Artery Bypass Grafting
- Conditions
- Interventions
- First Posted Date
- 2015-01-05
- Last Posted Date
- 2017-05-09
- Target Recruit Count
- 137
- Registration Number
- NCT02330640
- Locations
- 🇨🇳
FuWaiHospital, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.